Leelyn Smith LLC Buys 5,729 Shares of Pfizer Inc. $PFE

Leelyn Smith LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 99,337 shares of the biopharmaceutical company’s stock after acquiring an additional 5,729 shares during the period. Leelyn Smith LLC’s holdings in Pfizer were worth $2,408,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter valued at approximately $27,000. North Capital Inc. bought a new position in shares of Pfizer during the 1st quarter valued at approximately $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer during the 1st quarter valued at approximately $28,000. Harbor Asset Planning Inc. bought a new position in shares of Pfizer during the 2nd quarter valued at approximately $29,000. Finally, Horizon Financial Services LLC bought a new position in Pfizer in the 1st quarter worth approximately $35,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $24.79 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $140.92 billion, a P/E ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a fifty day moving average of $24.87 and a 200-day moving average of $24.17.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on PFE shares. Morgan Stanley reduced their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.